Business
Incannex Granted FDA Fast Track Designation for IHL-42X in Obstructive Sleep Apnea (OSA)
MELBOURNE, Australia and NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for IHL-42X, the Company’s oral fixed-dose combination product candidate for the treatment of obstructive sleep apnea (OSA). The Fast Track designation was supported by promising safety, efficacy, and pharmac
About this update from Incannex Healthcare Inc.
[{"type":"image","alt":"Incannex Healthcare","displaySize":"","headline":null,"caption":"Incannex Healthcare","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":50,"url":"https://media.zenfs.com/en/globenewswire.com/27f6059234ed425fa359634ca773e7f7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/JtZ_G8jXkVENc6BFL9UpGQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTcwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/27f6059234ed425fa359634ca773e7f7","width":300,"height":50}},"lazy":false},{"type":"text","content":"MELBOURNE, Australia and NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for IHL-42X, the Company’s oral fixed-dose combination product candidate for the treatment of obstructive sleep apnea (OSA).","length":416,"tagName":"p"},{"type":"text","content":"The Fast Track designation was supported by promising safety, efficacy, and pharmacokinetic results from the three clinical trials completed to date within the IHL-42X development program. These include the Company’s successful Phase 2 “RePOSA” study demonstrating statistically significant reductions in Apnea-Hypopnea Index (AHI), with individual reductions of up to 83%, outstanding patient-reported outcomes, and an excellent safety profile.","length":445,"tagName":"p"},{"type":"text","content":"Fast Track designation is granted by the FDA to drug candidates that treat serious conditions and address unmet medical needs with the aim of making important new therapies available to patients sooner.","length":202,"tagName":"p"},{"type":"text","content":"Under the Fast Track program, IHL-42X will now benefit from:","length":60,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"More frequent, structured interactions between Incannex and the FDA to discuss clinical strategy, trial design, and data requirements","length":133,"tagName":"p"}]},{"val":[{"type":"text","content":"Eligibility for rolling review, enabling the Company to submit completed sections of a future New Drug Application (NDA) ahead of the full submission","length":149,"tagName":"p"}]},{"val":[{"type":"text","content":"Potential access to Accelerated Approval and Prior...